Key facts
- Medyria’s last known valuation is $29.3M (Jul 2025).
- It has raised $16.2M; the latest was Later Stage VC ($1.9M) in Jul 2025.
- Notable investors include Venture Kick, Verve Ventures, Zürcher Kantonalbank, Buenavista Equity Partners, Buenavista Equity Partners Portugal — 12 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 12 names
- ·Watchlist + deal alerts for Medyria
- ·The full record, as it builds
Funding rounds
No funding rounds for Medyria are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Medyria
Developer of a next-generation physiology assessment device intended to advance the diagnosis and treatment of heart ischemia. The company offers a comprehensive system capable of assessing full cardiovascular function and detecting early signs of ischemia, enabling healthcare professionals to intervene sooner and prevent progression to myocardial infarction.
- Sector
- Healthcare
- HQ
- Winterthur, Switzerland
- Founded
- 2012
- Employees
- 9
- Website
- medyria.com/
- Ownership
- Privately Held (backing)
Medyria doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Medyria shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Medyria in its N-PORT filings yet. We sweep new filings monthly.